← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA4913.6x18.8x25.3x
EV / LTM revenue1021.8x3.0x6.2x
Premium to unaffected price13825%39%60%
Premium to 30-day VWAP2430%42%62%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
012242010: 12 deals, 2 clean on every measure2010122011: 11 deals, 6 clean on every measure2011112012: 16 deals, 9 clean on every measure2012162013: 12 deals, 6 clean on every measure2013122014: 19 deals, 10 clean on every measure2014192015: 10 deals, 4 clean on every measure2015102016: 13 deals, 8 clean on every measure2016132017: 12 deals, 9 clean on every measure2017122018: 14 deals, 6 clean on every measure2018142019: 15 deals, 6 clean on every measure2019152020: 12 deals, 6 clean on every measure2020122021: 18 deals, 14 clean on every measure2021182022: 15 deals, 11 clean on every measure2022152023: 24 deals, 12 clean on every measure2023242024: 14 deals, 10 clean on every measure2024142025: 23 deals, 13 clean on every measure2025232026: 16 deals, 7 clean on every measure202616
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 18.8x median across 49 dealsHealthcare18.8xn=49Technology: 18.2x median across 96 dealsTechnology18.2xn=96Financials: 17.7x median across 11 dealsFinancials17.7xn=11Real Estate: 17.2x median across 20 dealsReal Estate17.2xn=20Business Services: 13.2x median across 27 dealsBusiness Services13.2xn=27Industrials: 12.9x median across 73 dealsIndustrials12.9xn=73Utilities: 10.8x median across 37 dealsUtilities10.8xn=37Materials: 9.7x median across 22 dealsMaterials9.7xn=22Other: 9.5x median across 19 dealsOther9.5xn=19Energy: 9.5x median across 22 dealsEnergy9.5xn=22Consumer & Retail: 9.5x median across 74 dealsConsumer & Retail9.5xn=74Media & Telecom: 9.4x median across 20 dealsMedia & Telecom9.4xn=20
Deals by sector
Financials: 316 dealsFinancials316Technology: 287 dealsTechnology287Healthcare: 256 dealsHealthcare256Industrials: 189 dealsIndustrials189Consumer & Retail: 157 dealsConsumer & Retail157Energy: 106 dealsEnergy106Real Estate: 106 dealsReal Estate106Business Services: 96 dealsBusiness Services96Media & Telecom: 82 dealsMedia & Telecom82Utilities: 66 dealsUtilities66Materials: 59 dealsMaterials59Other: 53 dealsOther53
Deals by buyer type
Financial sponsor: 18 dealsFinancial sponsor18Strategic: 256 dealsStrategic256Management / founder: 1 dealsManagement / founder1Controlling holder: 2 dealsControlling holder2Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 160 dealsUnclassified160
Deals by enterprise value
Under $250m: 92 dealsUnder $250m92$250m to $1bn: 51 deals$250m to $1bn51$1bn to $5bn: 65 deals$1bn to $5bn65$5bn to $20bn: 43 deals$5bn to $20bn43Over $20bn: 4 dealsOver $20bn4Not computed: 1 dealsNot computed1
Deals by industry code
Chemicals, Pharmaceuticals & Allied Products: 151 dealsChemicals, Pharmaceutic…151Instruments, Medical Devices & Optical Goods: 65 dealsInstruments, Medical De…65Health Services: 40 dealsHealth Services40
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
Sanara MedTech Inc.
2026-07-29 · Public merger · $33.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
MiMedx Group, Inc.
Strategic
Healthcare$334m19.9x3.0x
35%
DEFM14A
Includes stock
Biolife Solutions Inc
2026-07-21 · Public merger · $11.25 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price; EV / LTM EBITDA 99.4x outside 1x to 75x
Repligen Corporation
Strategic
Healthcare$467m99.4x4.5x
15%
DEFM14A
Includes stock
Personalis, Inc.
2026-07-20 · Take-private · $16.25 a share
Board book on file →
Aviary Development, Inc
Strategic
Healthcare$1.5bnn.a.21.4x
n.a.
SC 13E3
All cash
AtaiBeckley Inc.
2026-07-15 · Public merger · $6.75 a share
Held out of the multiples: EV / LTM revenue 519.8x above 60x
Eli Lilly
Strategic
Healthcare$2.3bnn.a.519.8x
n.a.
40% to VWAP
DEFM14A
All cash
Crinetics Pharmaceuticals, Inc.
2026-07-06 · Public merger · $85.00 a share
Held out of the multiples: EV / LTM revenue 183.8x above 60x
Vertex Pharmaceuticals Incorporated
Strategic
Healthcare$7.8bnn.a.183.8x
101%
DEFM14A
All cash
Theravance Biopharma, Inc.
2026-06-28 · Public merger · $17.00 a share
Held out of the multiples: EV / LTM EBITDA 172.0x outside 1x to 75x
Zymeworks Inc.
Strategic
Healthcare$482m172.0x4.4x
n.a.
DEFM14A
All cash
BIO-TECHNE Corp
2026-06-25 · Public merger · $73.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Merck KGaA
Strategic
Healthcare$11bn44.9x9.4x
n.a.
DEFM14A
Includes stock
Apogee Therapeutics, Inc.
2026-06-18 · Public merger · $135.11 a share
Andor LLC, Inc.
Strategic
Healthcare$9.1bnn.a.n.a.
53%
DEFM14A
All cash
Catalyst Pharmaceuticals, Inc.
2026-05-06 · Public merger · $31.50 a share
Angelini Pharma S.p.A.
Strategic
Healthcare$3.1bn11.6x5.2x
21%
DEFM14A
All cash
Organon & Co.
2026-04-26 · Public merger · $14.00 a share
Sun Pharmaceutical Holdings USA, Inc.
Strategic
Healthcare$11bnn.a.1.8x
103%
120% to VWAP
DEFM14A
All cash
Galera Therapeutics, Inc.
2026-04-14 · Public merger · $1.75 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Obsidian Therapeutics, Inc.
Strategic
Healthcare$127mn.a.n.a.
n.a.
DEFM14C
Includes stock
Talkspace, Inc.
2026-03-09 · Public merger · $5.25 a share
Held out of the multiples: EV / LTM EBITDA 138.7x outside 1x to 75x
Universal Health Services, Inc.
Strategic
Healthcare$832m138.7x3.6x
10%
DEFM14A
All cash
Masimo Corp
2026-02-16 · Public merger · $180.00 a share
Danaher Corporation
Strategic
Healthcare$9.8bn28.0x6.4x
38%
DEFM14A
All cash
Aptose Biosciences Inc.
2026-01-15 (filed) · Take-private · $2.41 a share
Hanmi Pharmaceutical Co. LTD.
Strategic
Healthcare$5mn.a.n.a.
n.a.
28% to VWAP
SC 13E3
All cash
Penumbra Inc
2026-01-14 · Public merger · $374.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Boston Scientific
Strategic
Healthcare$14bn68.2x10.1x
n.a.
DEFM14A
Includes stock
Ventyx Biosciences, Inc.
2026-01-07 · Public merger · $14.00 a share
Eli Lilly
Strategic
Healthcare$806mn.a.n.a.
n.a.
62% to VWAP
DEFM14A
All cash
Fonar Corp
2025-12-23 · Take-private · $19.00 a share
Board book on file →
Hershowitz Limited Partnership
Strategic
Healthcare$63mn.a.0.6x
22%
SC 13E3
All cash
Amicus Therapeutics, Inc.
2025-12-19 · Public merger · $14.50 a share
Held out of the multiples: EV / LTM EBITDA 113.9x outside 1x to 75x
BioMarin Pharmaceutical Inc.
Strategic
Healthcare$4.6bn113.9x7.7x
33%
DEFM14A
All cash
Exact Sciences Corp
2025-11-19 · Public merger · $105.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Abbott Laboratories
Strategic
Healthcare$19bnn.a.6.1x
51%
DEFM14A
Includes stock
Sonnet BioTherapeutics Holdings, Inc.
2025-10-27 (filed) · Public merger · $1.25 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Biosub Inc.
Strategic
Healthcare$25mn.a.0.6x
n.a.
DEFM14A
Includes stock
Avidity Biosciences, Inc.
2025-10-25 · Public merger · $72.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price; EV / LTM revenue 426.4x above 60x
Distribution Agreement
Strategic
Healthcare$8.9bnn.a.426.4x
46%
DEFM14A
Includes stock
Akero Therapeutics, Inc.
2025-10-09 · Public merger · $54.00 a share
Novo Nordisk A/S
Strategic
Healthcare$3.6bnn.a.n.a.
42%
DEFM14A
All cash
Semler Scientific, Inc.
2025-09-22 · Public merger · $80.71 a share
Held out of every statistic: consideration includes stock: the cash figure is not the price; premium of 157%: distressed or misread
Strive, Inc.
Strategic
Healthcare$1.2bnn.a.27.5x
157%
DEFM14A
Includes stock
Metsera, Inc.
2025-09-21 · Public merger · $47.50 a share
Pfizer Inc.
Strategic
Healthcare$4.5bnn.a.n.a.
43%
DEFM14A
All cash
Evofem Biosciences, Inc.
2025-09-08 (filed) · Public merger · $116.75 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price; EV / LTM revenue 74.5x above 60x
Adifem, Inc.
Strategic
Healthcare$1.3bnn.a.74.5x
65%
DEFM14A
Includes stock

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More